Oike Takahiro, Ohno Tatsuya, Noda Shin-Ei, Kiyohara Hiroki, Ando Ken, Shibuya Kei, Tamaki Tomoaki, Takakusagi Yosuke, Sato Hiro, Nakano Takashi
Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Radiat Oncol. 2014 Oct 16;9:222. doi: 10.1186/s13014-014-0222-6.
Interstitial brachytherapy (ISBT) is an optional treatment for locally advanced gynecological tumours for which conventional intracavitary brachytherapy (ICBT) would result in suboptimal dose coverage. However, ISBT with Martinez Universal Perineal Interstitial Template (MUPIT), in which ~10-20 needles are usually applied, is more time-consuming and labor-intensive than ICBT alone, making it a burden on both practitioners and patients. Therefore, here we investigated the applicability of a combined intracavitary/interstitial (IC/IS) approach in image-guided adaptive brachytherapy for bulky and/or irregularly shaped gynecological tumours for which interstitial brachytherapy (ISBT) was performed.
Twenty-one consecutive patients with gynecological malignancies treated with computed tomography-guided ISBT using MUPIT were analyzed as cases for this dosimetric study. For each patient, the IC/IS plan using a tandem and 1 or 2 interstitial needles, which was modeled after the combined IC/IS approach, was generated and compared with the IS plan based on the clinical ISBT plan, while the IC plan using only the tandem was applied as a simplified control. Maximal dose was prescribed to the high-risk clinical target volume (HR-CTV) while keeping the dose constraints of D2cc bladder < 7.0 Gy and D2cc rectum < 6.0 Gy. The plan with D90 HR-CTV exceeding 6.0 Gy was considered acceptable.
The average D90 HR-CTV was 77%, 118% and 140% in the IC, IC/IS and IS plans, respectively, where 6 Gy corresponds to 100%. The average of the ratio of D90 HR-CTV to D2cc rectum (gain factor (GF) rectum) in the IC, IC/IS and IS plans was 0.8, 1.3 and 1.5 respectively, while GFbladder was 0.9, 1.4 and 1.6, respectively. In the IC/IS plan, D90 HR-CTV, GFrectum and GFbladder exceeded 100%, 1.0 and 1.0, respectively, in all patients.
These data demonstrated that the combined IC/IS approach could be a viable alternative to ISBT for gynecological malignancies with bulky and/or irregularly shaped tumours.
组织间近距离放疗(ISBT)是局部晚期妇科肿瘤的一种可选治疗方法,对于此类肿瘤,传统腔内近距离放疗(ICBT)会导致剂量覆盖不理想。然而,使用马丁内斯通用会阴组织间模板(MUPIT)的ISBT通常需要插入约10 - 20根针,比单独的ICBT更耗时且劳动强度更大,这给从业者和患者都带来了负担。因此,我们在此研究了腔内/组织间联合(IC/IS)方法在图像引导下的适形近距离放疗中对于需要进行组织间近距离放疗(ISBT)的体积较大和/或形状不规则的妇科肿瘤的适用性。
将连续21例使用MUPIT在计算机断层扫描引导下接受ISBT治疗的妇科恶性肿瘤患者作为该剂量学研究的病例进行分析。对于每位患者,生成基于串联和1根或2根组织间针的IC/IS计划(该计划仿照IC/IS联合方法制定),并与基于临床ISBT计划的IS计划进行比较,同时将仅使用串联的IC计划作为简化对照。将最大剂量规定给高危临床靶区(HR-CTV),同时保持膀胱D2cc < 7.0 Gy和直肠D2cc < 6.0 Gy的剂量限制。D90 HR-CTV超过6.0 Gy的计划被认为是可接受的。
在IC、IC/IS和IS计划中,平均D90 HR-CTV分别为77%、118%和140%(其中6 Gy对应100%)。IC、IC/IS和IS计划中D90 HR-CTV与直肠D2cc的比值(增益因子(GF)直肠)平均值分别为0.8、1.3和1.5,而GF膀胱分别为0.9、1.4和1.6。在IC/IS计划中,所有患者的D90 HR-CTV、GF直肠和GF膀胱均分别超过100%、1.0和1.0。
这些数据表明,对于体积较大和/或形状不规则肿瘤的妇科恶性肿瘤,IC/IS联合方法可能是ISBT的一种可行替代方案。